+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Age-related Macular Degeneration Market by Treatment (Non-Pharmacological, Pharmacological), Drug Class (Anti-Vegf, Corticosteroid), Type, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Age-related Macular Degeneration Market by Treatment (Non-Pharmacological, Pharmacological), Drug Class (Anti-Vegf, Corticosteroid), Type, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Age-related Macular Degeneration Market by Treatment (Non-Pharmacological, Pharmacological), Drug Class (Anti-Vegf, Corticosteroid), Type, End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 191 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5665786
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Age-related macular degeneration (AMD) is a complex and evolving therapeutic area experiencing rapid shifts in treatment innovation and market structure. As prevalence grows among aging populations, the need for informed, agile strategies across the AMD value chain is more critical than ever for senior decision-makers.

Market Snapshot: Age-related Macular Degeneration Market

The Age-related Macular Degeneration Market grew from USD 11.10 billion in 2024 to USD 11.82 billion in 2025. It is expected to continue growing at a CAGR of 6.75%, reaching USD 16.43 billion by 2030. The market trajectory reflects expanding therapeutic needs, integration of high-value biologics, and ongoing global demographic shifts. Changing reimbursement landscapes and technology adoption are accelerating pressure on both established and emerging market participants.

Scope & Segmentation

This report delivers a structured analysis of the global AMD market. The research dissects segment performance, therapeutic advancements, and regional developments for strategic clarity.

  • Treatment Approaches: Covers pharmacological strategies (including anti-VEGF and corticosteroid options) and non-pharmacological methods (such as laser and photodynamic therapies).
  • Drug Classes: Details anti-VEGF agents (aflibercept, bevacizumab, brolucizumab, ranibizumab) and corticosteroids (dexamethasone, triamcinolone).
  • Disease Types: Addresses dry and wet AMD classifications to support accurate clinical targeting.
  • End Users: Analyzes usage patterns across clinics, hospitals, and specialty ophthalmic centers.
  • Distribution Channels: Focuses on hospital, online, and retail pharmacies driving therapy access.
  • Regions: Examines market dynamics in the Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including key Western European, Middle Eastern, and African nations), and Asia-Pacific (China, India, Japan, Australia, South Korea, Southeast Asia, and others).
  • Companies: Profiles major players such as Regeneron Pharmaceuticals, Bayer, Novartis, F. Hoffmann-La Roche, Alcon, Carl Zeiss, Topcon Healthcare, Nidek, Heidelberg Engineering, and Optos.

Key Takeaways

  • Innovation is reshaping diagnosis and intervention, with high-resolution imaging and AI-driven screening enabling earlier detection and tailored treatment strategies.
  • Stakeholders are leveraging new drug delivery technologies—including sustained-release and implantable formulations—to improve adherence and reduce patient burden.
  • Gene therapies and complement pathway inhibitors are introducing novel options for dry AMD, expanding addressable market segments.
  • Value-based and risk-sharing contracts are gaining momentum as payers demand evidence of clinical and economic outcomes to justify coverage.
  • Regional market divergence reinforces the importance of tailored strategies; for example, Western Europe adopts advanced implants, while Asia-Pacific prioritizes infrastructure and digital integration to close care gaps.
  • Strategic collaborations—across diagnostics, digital health, and contract manufacturing—are central to pipeline expansion and supply chain resilience.

Tariff Impact: Navigating 2025 Supply Chain and Pricing Challenges

Recent U.S. tariffs have introduced complexities in therapeutic input sourcing and delivery device costs. Companies are adapting through supplier renegotiation, domestic production shifts, and strengthening logistics networks. These adjustments influence market access timelines and require ongoing optimization of supply chain resilience and risk management strategies to ensure continued patient access.

Methodology & Data Sources

This report combines extensive secondary research—including scientific literature, regulatory data, and corporate filings—with primary interviews of market experts and front-line clinicians. Quantitative findings were triangulated using independent datasets and validated via consistency checks. Methodological rigor and transparency underpin all conclusions and recommendations.

Why This Report Matters

  • Equips executive teams with a clear perspective on innovation-driven trends, helping guide investment, R&D prioritization, and market entry strategies for AMD therapeutics.
  • Supports supply chain optimization decisions and regional go-to-market planning in response to evolving regulatory and economic variables.

Leveraging these insights enables stakeholders to capture emerging growth opportunities and navigate the competitive landscape confidently.

Conclusion

The AMD market is advancing through shifts in technology, treatment delivery, and policy. Organizations harnessing early detection, diversified supply, and collaborative approaches will be well placed to drive improved outcomes for patients and stakeholders alike.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Approval and market adoption of gene therapy approaches for dry age-related macular degeneration
5.2. Emergence of anti-VEGF biosimilars reducing treatment costs and expanding patient access
5.3. Development of sustained-release intravitreal implants to reduce injection frequency in AMD patients
5.4. Integration of artificial intelligence algorithms for early diagnosis and progression monitoring of AMD
5.5. Expansion of teleophthalmology platforms to deliver remote monitoring and virtual consultations for AMD management
5.6. Growing emphasis on personalized nutrition and lifestyle interventions to slow AMD progression in aging populations
5.7. Advancements in high-resolution retinal imaging devices for more precise monitoring of macular degeneration progression
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Age-related Macular Degeneration Market, by Treatment
8.1. Introduction
8.2. Non-Pharmacological
8.2.1. Laser Therapy
8.2.2. Photodynamic Therapy
8.3. Pharmacological
9. Age-related Macular Degeneration Market, by Drug Class
9.1. Introduction
9.2. Anti-Vegf
9.2.1. Aflibercept
9.2.2. Bevacizumab
9.2.3. Brolucizumab
9.2.4. Ranibizumab
9.3. Corticosteroid
9.3.1. Dexamethasone
9.3.2. Triamcinolone
10. Age-related Macular Degeneration Market, by Type
10.1. Introduction
10.2. Dry
10.3. Wet
11. Age-related Macular Degeneration Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Hospitals
11.4. Specialty Ophthalmic Centers
12. Age-related Macular Degeneration Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Americas Age-related Macular Degeneration Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Age-related Macular Degeneration Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Age-related Macular Degeneration Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Regeneron Pharmaceuticals, Inc.
16.3.2. Bayer AG
16.3.3. Novartis AG
16.3.4. F. Hoffmann-La Roche AG
16.3.5. Alcon Inc.
16.3.6. Carl Zeiss AG
16.3.7. Topcon Healthcare, Inc.
16.3.8. Nidek Co., Ltd.
16.3.9. Heidelberg Engineering GmbH
16.3.10. Optos plc
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. AGE-RELATED MACULAR DEGENERATION MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2024 VS 2030 (%)
FIGURE 6. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AGE-RELATED MACULAR DEGENERATION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. AGE-RELATED MACULAR DEGENERATION MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. AGE-RELATED MACULAR DEGENERATION MARKET: RESEARCHAI
FIGURE 26. AGE-RELATED MACULAR DEGENERATION MARKET: RESEARCHSTATISTICS
FIGURE 27. AGE-RELATED MACULAR DEGENERATION MARKET: RESEARCHCONTACTS
FIGURE 28. AGE-RELATED MACULAR DEGENERATION MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. AGE-RELATED MACULAR DEGENERATION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY LASER THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TRIAMCINOLONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TRIAMCINOLONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SPECIALTY OPHTHALMIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SPECIALTY OPHTHALMIC CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 101. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 102. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 103. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
TABLE 104. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2030 (USD MILLION)
TABLE 105. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 106. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 107. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 108. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 109. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
TABLE 110. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2030 (USD MILLION)
TABLE 111. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 112. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 113. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 114. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 115. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 118. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 119. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
TABLE 120. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2030 (USD MILLION)
TABLE 121. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 122. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 123. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 124. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 125. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
TABLE 126. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2030 (USD MILLION)
TABLE 127. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 128. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 129. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 200. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 201. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
TABLE 202. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2030 (USD MILLION)
TABLE 203. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 204. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 205. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 206. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 207. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
TABLE 208. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2030 (USD MILLION)
TABLE 209. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 210. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 211. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 216. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 217. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
TABLE 218. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2030 (USD MILLION)
TABLE 219. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 220. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 221. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 222. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 223. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
TABLE 224. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2030 (USD MILLION)
TABLE 225. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 226. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 227. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 232. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 248. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 249. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
TABLE 250. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2030 (USD MILLION)
TABLE 251. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 252. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 253. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 254. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 255. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
TABLE 256. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2030 (USD MILLION)
TABLE 257. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 258. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 259. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 264. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 265. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
TABLE 266. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2030 (USD MILLION)
TABLE 267. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 268. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 269. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 270. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 271. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
TABLE 272. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2030 (USD MILLION)
TABLE 273. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 274. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 275. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
TABLE 296. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
TABLE 298. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET S

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Age-related Macular Degeneration market report include:
  • Regeneron Pharmaceuticals, Inc.
  • Bayer AG
  • Novartis AG
  • F. Hoffmann-La Roche AG
  • Alcon Inc.
  • Carl Zeiss AG
  • Topcon Healthcare, Inc.
  • Nidek Co., Ltd.
  • Heidelberg Engineering GmbH
  • Optos plc

Table Information

Report AttributeDetails
No. of Pages191
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 11.82 Billion
Forecasted Market Value ( USD ) by 2030 $ 16.43 Billion
Compound Annual Growth Rate6.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Age-Related Macular Degeneration (AMD) - Pipeline Insight, 2025 - Product Image

Age-Related Macular Degeneration (AMD) - Pipeline Insight, 2025

  • Clinical Trials
  • 280 Pages
  • Global
From
Dry Age-related Macular Degeneration (Dry-AMD)- Pipeline Insight, 2025 - Product Image

Dry Age-related Macular Degeneration (Dry-AMD)- Pipeline Insight, 2025

  • Clinical Trials
  • 240 Pages
  • Global
From
Macular Degeneration Drug Pipeline Analysis Report 2025 - Product Image

Macular Degeneration Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Wet Age-Related Macular Degeneration (Wet AMD) Market - A Global and Regional Analysis: Focus on Treatment Type, and Region - Analysis and Forecast, 2025-2035 - Product Image

Wet Age-Related Macular Degeneration (Wet AMD) Market - A Global and Regional Analysis: Focus on Treatment Type, and Region - Analysis and Forecast, 2025-2035

  • Report
  • 100 Pages
  • Global
From
Macular Degeneration Pipeline Analysis Report - Product Image

Macular Degeneration Pipeline Analysis Report

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.